Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Expected to Reach $3,528.8 Million, by 2026

According to a new report published by Allied Market Research, titled,"Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market by Drug and Type: Global Opportunity Analysis and Industry Forecast, 2019 - 2026" the global acute lymphocytic/lymphoblastic leukemia therapeutics market size was valued at $2,334.5 million in 2018, and is projected to reach $3,528.8 million by 2026, growing at a CAGR of 5.3% from 2019 to 2026.

Acute lymphocytic/lymphoblastic leukemia (ALL) is one of the types of leukemia, which is highly prevalent in pediatrics and also observed in adults. There are various therapy options for ALL treatment including chemotherapy, targeted therapy, and immunotherapy. ALL treatments witness high success rates in pediatric population, however, in adult population have low success rates. Chemotherapy is a first line treatment option in majority of ALL cases.

Rise in incidences of acute lymphoblastic leukemia and the number of bone marrow biopsies across the world are the major factors that boost the growth of the acute lymphocytic/lymphoblastic leukemia therapeutics market. However, the stringent regulatory approvals for the therapeutics and the adverse side effect of the drugs used in the therapy impede the acute lymphocytic/lymphoblastic leukemia therapeutics market growth. The increase in investment in the R&D of different leukemia and rise in awareness of targeted therapies amongst the population are also anticipated to provide lucrative opportunities for the market during the forecast period.

On the basis of drug, the Hyper-CVAD Regimen acquired the largest acute lymphocytic/lymphoblastic leukemia therapeutics market share in 2018 owing to their wide usage in ALL treatment. Hyper-CVAD Regimen is considered as one of the most commonly used therapy options for acute lymphocytic/lymphoblastic leukemia. Furthermore, targeted drugs & immunotherapy are projected to grow at the fastest rate during the forecast period as these drugs have shown potential in treatment of relapsed acute lymphocytic leukemia and is widely used in patients who do not respond to chemotherapy. Therefore, these factors contribute toward the growth of the acute lymphocytic/lymphoblastic leukemia therapeutics market.

According to type, the pediatrics segment generated the highest revenue in 2018 and is expected to maintain its dominance throughout the forecast period. This is attributed to the high incidences of acute lymphocytic/lymphoblastic leukemia among pediatric population. Acute lymphocytic/lymphoblastic leukemia is considered as one of the most common cancer types in pediatric population. Moreover, pediatric population has higher success rate for acute lymphocytic/lymphoblastic leukemia treatments.

In 2018, North America occupied the largest share of the market and is expected to maintain its dominance during the forecast period owing to easy availability of treatments, high cost of treatments, and presence of majority of key players. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period

Key Findings of the Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market:

• The pediatrics segment accounted for more than half of the market share in 2018.
• North America accounted for more than one-third market share in 2018 and is expected to maintain this trend throughout the forecast period.
• The targeted drugs & immunotherapy in the end user segment is anticipated to grow at a CAGR of 6.7% from 2018 to 2026.
• The adults segment accounted for 44% share of the market in 2018.